ReviewMedicine and pharmacy reports2025
Clinical aspects encountered in patients with portopulmonary hypertension.
Review in Medicine and pharmacy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portopulmonary hypertension (PoPH) is a condition characterized by the elevation of the arterial pulmonary pressure because of portal hypertension which leads to right heart failure and finally death. The most common cause of PoPH is hepatic cirrhosis, but patients with non-cirrhotic portal hypertension can also develop this complication. It is considered that between 2% and 10% of patients with portal hypertension can develop PoPH, and it is a major determinant factor of prognosis, especially in the context of liver transplantation. Clinically, the symptoms are nonspecific and are usually due to worsening right ventricular dysfunction. The treatment of PoPH consists of vasomodulating therapy, but several future challenges remain in the treatment of PoPH patients. In the absence of medical treatment or liver transplantation, the 1-year survival rate is 35%-46% and 5-year survival rate is 4-14%. Despite advances in understanding this disease, several unresolved questions remain regarding screening, diagnosis, treatment, and liver transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.